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Abstract
Background: Hepatitis E is endemic to resource-poor regions, where it manifests as sporadic cases and large
waterborne outbreaks. The disease severity ranges from acute self-limited hepatitis with low mortality to fulminant
hepatic failure with high mortality. It is believed that the host response plays an important role in determining the
progression and outcome of this disease. We profiled the plasma peptidome from hepatitis E patients to discover
suitable biomarkers and understand disease pathogenesis.
Results: The peptidome (< 10 kDa) fraction of plasma was enriched and analyzed by mass spectrometry. A
comparative analysis of the peptide pattern of hepatitis E patients versus healthy controls was performed using
ClinPro Tools. We generated a peptide profile that could be used for selective identification of hepatitis E cases. We
have identified five potential biomarker peaks with m/z values of 9288.6, 7763.6, 4961.5, 1060.572 and 2365.139 that
can be used to reliably differentiate between hepatitis E patients and controls with areas under the receiver
operating characteristic curve (AUROC) values of 1.00, 0.954, 0.989, 0.960 and 0.829 respectively. A number of
proteins involved in innate immunity were identified to be differentially present in the plasma of patients
compared to healthy controls.
Conclusions: Besides the utility of this approach for biomarker discovery, identification of changes in endogenous
peptides in hepatitis E patient plasma has increased our understanding of disease pathogenesis. We have identified
peptides in plasma that can reliably distinguish hepatitis E patients from healthy controls. Results from this and an
earlier proteomics study are discussed.
Background
Hepatitis E, caused by infection with the enterically
transmitted hepatitis E virus (HEV), is a common form
of hepatitis in areas with poor sanitation and hygiene. It
causes an acute self-limiting disease mainly in young
adults with a low mortality of 0.2% to 1.0% in the gen-
eral population. However, in some cases the disease pro-
gresses to fulminant hepatic failure (FHF) with high
mortality. For reasons yet not determined, there is
increased incidence and severity in pregnant women
infected during the second and the third trimester with
mortality rates between 15-25% [1,2]. Hepatitis E is
endemic to large parts of Asia, Africa, the Mediterra-
nean region, Mexico and South America, where it is
responsible for outbreaks that are often large, and affect
several hundred to several thousand people [3]. In dis-
ease-endemic areas, HEV infection also accounts for a
large proportion of acute sporadic hepatitis in all age
groups. It is estimated that about 2 billion people live in
areas endemic for HEV [4].
The geographic prevalence of antibody to HEV is
worldwide. In India, HEV infection is the most common
cause of acute sporadic hepatitis and accounts for up to
50% of such cases among adults. In developed countries,
the disease was initially found to occur almost exclu-
sively among travellers to disease-endemic regions. Over
the past few years, there has been an increase in the
number of autochthonous cases in developed countries
and evidence for a possible zoonotic reservoir is also
reported, which has revived worldwide interest in this
disease [5]. To understand the pathogenesis of hepatitis
E and to identify new candidate biomarkers that could
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be helpful in its clinical management, we have probed
patients for changes in their plasma peptidome by mass
spectrometry. The application of mass spectrometry to
proteomics [6] and peptidomics [7] holds considerable
promise for the discovery of new bioactive molecules
and for elucidating biochemical regulatory networks.
Endogenous peptides have already been established as
messengers, hormones or cytokines in many physiological
processes. In addition, peptides can be derived from the
turnover of blood or tissue proteins. Alterations in peptide
levels under disease conditions implicate this class of
molecules as potential biomarkers. A limited number of
studies have concentrated on naive, circulating peptides,
also referred to as peptidome (i.e. the low molecular
weight proteome) in blood [8-10]. We have applied a mag-
netic bead based separation strategy to enrich hydrophobic
peptides from plasma, which are then analyzed by
MALDI-TOF. Endogenous plasma peptides from patients
with acute hepatitis E were compared to healthy controls
and differential pattern analysis was performed. The differ-
ences have identified discriminating marker peptides for
acute HEV infection and these are discussed with a view
to better understand disease pathogenesis.
Methods
Materials
Acetonitrile (ACN; HPLC grade) was obtained from SD
Fine Chemicals (New Delhi, India). Trifluoroacetic acid
(TFA) was purchased from Sigma-Aldrich (St. Louis,
USA). The peptide and protein calibrants, and a-cyano-4-
hydroxycinnamic acid (MALDI-MS matrix) were pur-
chased from Bruker Daltonics, Germany. The matrix was
prepared as 10 mg/ml a-cyanohydroxycinnamic acid in
ACN/0.1% TFA (1:2). For magnetic bead preparations, we
used RPC-18 Dynal Beads and Dynal MPC magnetic stand
from Invitrogen (New York, USA). Two calibration stan-
dards were used for external calibration of the spectra gen-
erated with the reflectron positive (RP) mode containing
the following peptide mass (monoisotopic): (M+H)+ Bra-
dykinin (1-7) - 755.39916; angiotensin II - 1046.54180;
angiotensin I - 1296.684780; substance P - 1347.735430;
bombesin - 1619.822350; renin substrate - 1758.932610;
ACTH_clip (1-17) - 2093.086170; ACTH_clip (18-39) -
2465.198340; Somatostatin - 3147.47100 and the linear
positive (LP) mode containing Insulin (M+H)+ (avg) -
5734.5200, Cytochrome C (M+2H)2+ - 6181.0500;
Myoglobin (M+2H)2+ - 8476.6600; Ubiquitin-I (M+H)+
(avg) - 8565.7600; Cytochrome C (M+H)+ (avg) -
12360.9700; Myoglobin (M+H)+ (avg) - 16952.3100.
Subjects
Specimens were obtained from patients with jaundice at
the Gastroenterology Outpatient Clinic or inpatients at
the Army Base Hospital, New Delhi, and Sanjay Gandhi
Postgraduate Institute of Medical Sciences, Lucknow,
India. All the samples were collected from male patients
and the mean age was 31 yrs ± 9. All the patients had
clinically diagnosed hepatitis with mean bilirubin levels
as 10.11 mg/dl, SGOT levels as 504.8 IU/ml, and SGPT
levels as 814.09 IU/ml (Table 1). Specimens were also
obtained from healthy volunteers. The study was
approved by the Human Subjects Ethics Committee at
ICGEB and the respective hospitals, and informed con-
sent was obtained prior to sampling. Blood (5-6 ml) was
collected in EDTA-coated vacutainers (Becton Dickinson,
Maryland, USA), and centrifuged at 800xg for 5 min at
4°C. The plasma was collected and stored in aliquots at
-70°C. It was tested for various viral hepatitis markers by
enzyme immunoassays (EIA) as follows: HBsAg (Hepa-
lisa, J Mitra and Co. Pvt. Ltd., New Delhi, India), anti-
HCV (Hep-Chex-C, XCyton Diagnostic Pvt. Ltd., Banga-
lore, India), and IgM anti-HEV (HEV IgM ELISA, MP
Biomedicals Asia Pacific Pvt. Ltd., Singapore) as per the
manufacturer’s protocols. Samples positive for IgM anti-
HEV and negative for HCV and HBV markers were
selected and grouped together as HEV+ samples.
Peptidome Separation
Dynal beads are supermagnetic, monosized polymer par-
ticles with attached bioreactive molecules, which lead to
specific surface chemistries that are useful for the
separation of biomolecules. The chemical specificities of
these beads include reverse phase (RPC18), strong or
weak cation exchange (SCX or WCX), and strong anion
exchange (SAX). The ligand on RPC18 binds to non-
polar amino acids of proteins or peptides through strong
hydrophobic adsorption interactions and are eluted
using an organic solvent e.g. acetonitrile.
Dynal RPC 18 beads were resuspended thoroughly to
obtain a homogeneous suspension. Of these, 20 μL (0.25
mg) were transferred to a tube and placed on a magnet
(Dynal MPC) for 1-2 min. The supernatant was
removed by aspiration while the tube remained on the
magnet. The tube was removed, 100 μL of washing solu-
tion (0.1% Trifluoroacetic acid) was applied along the
inside of the tube where the beads were collected and
resuspended. This step was repeated for a total of 3-4
washes, after which 10 μL of washing solution was
added and the beads were resuspended. Five μL of
plasma sample was added to the vial containing pre-
washed beads, 15 μL more of the washing solution was
added and the contents were mixed using a pipette. It
was left at room temperature for 2 min to allow the
peptides to adsorb to the beads and the tube was placed
on the magnet. When the beads were at the tube wall
and the liquid was clear, the supernatant was removed
and discarded. The tube was removed from the magnet
and 50 μL of washing solution was added and mixed.
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The beads were washed with three changes of washing
solution and the supernatant discarded after magnetic
separation. The beads were finally resuspended in 6 μL
desorption solution (50% acetonitrile), incubated for
2 min at room temperature and the eluate was removed
after magnetic separation from the beads.
MALDI -TOF/TOF Analysis
For this analysis, 1 μL of the eluate was mixed with 1 μL
of MALDI-MS matrix and spotted onto a MALDI
ground steel target plate (Bruker Daltonics, GmbH).
Each sample was spotted in triplicate on the plate and
was left to dry for 30 min. Samples and calibration stan-
dards with the same matrix composition were spotted
adjacent to each other on the target plate for optimal
calibration. Spectra generated with the reflectron posi-
tive (RP) mode and the linear positive (LP) mode were
externally calibrated with the calibration standards as
explained in the ‘Materials’ section. Measurements were
performed using an Ultraflex MALDI-TOF/TOF
Table 1 Epidemiological data of the patients (P) and healthy controls (N) recruited in the study
Patient ID Age
(years)
Sex HEV IgM HBsAg HCV IgG Bilirubin
(mg/dl)
SGOT
(IU/ml)
SGPT
(IU/ml)
P1 58 Male + - - 19.1 41 71
P2 39 Male + - - ND ND ND
P3 21 Male + - - 2.9 ND ND
P4 14 Male + - - 9.4 620 934
P5 25 Male + - - 9.5 280 476
P6 24 Male + - - 4.6 86 172
P7 22 Male + - - 9.8 106 192
P8 26 Male + - - 14 386 820
P9 30 Male + - - 8 292 640
P10 22 Male + - - 5.8 230 510
P11 30 Male + - - 9.6 193 334
P12 35 Male + - - 4.6 116 328
P13 33 Male + - - 6.4 195 393
P14 24 Male + - - 8.5 810 1040
P15 39 Male + - - 4.1 202 265
P16 31 Male + - - 9.1 356 470
P17 24 Male + - - 8.2 219 348
P18 36 Male + - - 17 1453 1503
P19 34 Male + - - 20.9 1008 1170
P20 29 Male + - - 12.8 1956 2696
P21 23 Male + - - 12.5 69 176
P22 35 Male + - - 5.2 464 1476
P23 40 Male + - - 10.4 159 340
P24 36 Male + - - 6.1 2309 4266
P25 51 Male + - - 24.3 61 104
N1 45 Male - - - ND ND ND
N2 30 Male - - - ND ND ND
N3 33 Male - - - ND ND ND
N4 31 Male - - - ND ND ND
N5 27 Male - - - ND ND ND
N6 31 Male - - - ND ND ND
N7 27 Male - - - ND ND ND
N8 28 Male - - - ND ND ND
N9 31 Male - - - ND ND ND
N10 28 Male - - - ND ND ND
ND: Not done.
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instrument (Bruker Daltonics, GmbH), in the positive
ion linear and reflector mode with the accelerating vol-
tage of 25 kV (Ion source 1) and 21.85 kV (Ion source 2)
respectively. The laser wavelength and frequency was 337
nm and 67-100 Hz and the percentage was set to 25%.
The detector range was set at 400-4000 Da for the reflec-
tron positive mode and 1000-10000 Da for the linear
positive mode. Final mass spectra were produced by aver-
aging 1500 laser shots taken at five different positions
within each spot. It was processed using the AutoXecute
tool of the Flex Control acquisition software. For data
analysis, Bruker Daltonics ClinPro Tools (CPT) Software
(v2.0) was applied. The CPT workflow starts by spectra
loading of two selected classes (HEV+ cases and healthy
controls). The CPT software package included an auto-
mated raw data pre-treatment workflow, comprising
baseline subtraction with 80% baseline flatness (Convex
Hull v3), normalization of spectra according to the total
ion count and an alignment of peaks with threshold of
signal-to-noise ratio (S/N) >5 for peaks and Savitzky-
Golay smoothing (1 cycle, m/z range = 5). Peaks with
Kruskal-Wallis p-value > 0.1 were discarded. Peak statis-
tics were done using Genetic Algorithm. Finally, the soft-
ware provided a list of peaks sorted along the statistical
difference between two classes, which was used for
further data analysis.
MS/MS based sequencing and identification
For MS/MS based sequencing and identification of pro-
teins from the peptides, the precursor peptide ions were
fragmented in positive mode using the MALDI-MS/MS
sequencing method. The accelerating voltages were 8.00
kV and 7.15 kV for ion sources 1 and 2, respectively.
The reflector 1 and 2 were set to 29.5 kV and 13.9 kV
respectively, with Lift 1 and 2 respectively set at 19 kV
and 2.8 kV. Calibration was done using angiotensin II
and substance P as precursor mass. Fragmentation was
done using laser induced dissociation (LID), the frag-
mented peptide was analysed using Flex Analysis soft-
ware v3.0 and database search was done using Biotools
software v3.2 http://www.bdal.com/products/software/
biotools/overview.html. The database search parameters
were set as described, the taxonomy was set to Homo
sapiens and fragment masses were searched in the
National Centre for Biotechnology Information database
with MS tolerance of 0.1 Da and MS/MS tolerance of
0.5 Da.
Results
A total of 40 subjects, including 30 patients with acute
hepatitis E and 10 healthy controls were recruited for
the study. The plasma samples (5 μL of each sample),
were processed with Dynalbeads-RPC18 for enrichment
of the hydrophobic peptides as described in Methods.
Peptide mass fingerprints (PMF) of each sample were
generated in the mass range of 400-10000 Da in the two
different acquisition modes. The PMFs were loaded into
ClinPro Tools (CPT) and processed (Figure 1).
Model generation and validation
In the discovery phase, two models were generated
based on the acquisition modes, for the peptidome pro-
filing of HEV patient plasma cross-tested against healthy
controls. The Reflectron Positive (RP) Model was gener-
ated for peaks in the mass range of 400-4000 Da using
10 HEV+ samples and 4 healthy controls, designated as
Class 1 and 2, respectively for the Clinpro analysis. The
model which could correctly classify disease and control
samples was generated using the following parameters:
maximum number of best peaks - 20; number of gen-
erations - 50; number of nearest neighbours - 3; muta-
tion rate - 0.20. Analysis was performed and CPT
generated a table ranking the mass spectral peaks in
order of their p-values calculated using the statistical
tests: P-value of student ‘t’ test and analysis of variance
(p value tta) and P-value of Wilcoxon/Kruskal-Wallis
test (p value wkw). According to these tests and manual
validation, 31 peaks were identified as statistically signif-
icant between the two classes. Four peaks with m/z of
759.362, 887.466, 935.396 and 1778.074 that were upre-
gulated in hepatitis E patient plasma and six peaks with
m/z of 904.457, 1060.572, 1076.567, 1211.660, 1498.794
and 2365.139 that were downregulated in HEV infection
were selected (Figure 2, 3, 4). These 10 peaks were then
used for further validation. In the validation phase, 6
specimens each from the two classes were tested in a
blinded manner; these samples were different from
those used for model generation. Data analysis using
Clinpro software and manual inspection could efficiently
distinguish between the two classes of patients and con-
trols with a recognition capability of 96%. The other
mode of data acquisition was the linear positive mode.
The Linear Positive (LP) Model for peaks in the range
of 1000-10000 Da was generated using 11 HEV+ and 4
healthy control samples, again in a blinded manner with
new samples. Analysis was done with genetic algorithm
to identify the discriminating peaks. Using the statistical
tests and manual validations, a total of 102 discriminat-
ing peaks were identified. Of these, 7 peaks were
selected for the validation phase. These included 4
peaks that were upregulated in hepatitis E patient
plasma with m/z values of 1778.6, 4961.5, 7763.6 and
9288.6, and 3 peaks that were downregulated in HEV
infection with m/z values of 1060.5, 1098.6 and 5157.8
(Figure 5, 6). For the validation phase, 6 samples each in
the two classes were studied in a blinded manner. Man-
ual inspection of peaks and Clinpro analysis could effi-
ciently distinguish between patients and healthy
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individuals with a recognition capability of 100%. In the
RP mode, hepatitis E patients and healthy controls
showed discriminating peaks in the m/z ranges of 600
to 2600 Da (Figure 2), 700 to 1100 Da (Figure 3) and
1050 to 1800 Da (Figure 4). The discriminating peak
profiles acquired by the LP mode are shown in the m/z
ranges of 1000 to 10000 Da (Figure 5) and 4000 to
10000 Da (Figure 6). The smaller discriminating peaks
are shown in insets in Figure 3, 4 and 5. Density plots
showing differentially regulated peptides identified by
the RP and LP modes are also shown in Figure 7A and
7B, respectively.
Receiver Operating Characteristic Curve
The receiver operating characteristic (ROC) curve plots
correct identifications (i.e. sensitivity) and misidentifica-
tions (1-specificity) when using a diagnostic test, and
provides a graphical representation of the latter’s effec-
tiveness in discriminating between two groups. The area
under the ROC curve (AUROC) is a reflection of test
reliability in discriminating two sets, these being HEV
patients and healthy controls in our case. The ROC
curves were generated using intensity data from 25
patients and 7 controls. The intensity value of each peak
was taken into account. Each sample was subjected to
MS acquisition in triplicates and the intensity of the
same peak in at least two of the spectra was averaged
and used for the ROC calculation. The AUROC values
above 0.75 are considered to provide good discrimina-
tion [11]. Based on the quantitative data of peak intensi-
ties, the AUROC for peaks with m/z values of 9288.6,
7763.6 and 4961.5, which increase in HEV patient
plasma were found to be 1.00, 0.954 and 0.989 respec-
tively with 95% confidence intervals of 1.00-1.00 for
Figure 1 Schematic representation of peptidome enrichment and analysis. The methodology used for the enrichment and analysis of
plasma peptides is shown. After enrichment of hydrophobic peptides using RPC-18 magnetic beads, the peptide fraction was subjected to mass
spectrometry using two different acquisition modes. ClinPro Tools was used for model generation using pattern analysis of the peptide mass
fingerprints of patients or controls and the differentiating peaks were identified using MS/MS. Following the discovery phase, different blinded
samples were used for validation.
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peak m/z 9288.6, 0.876-1.033 for peak m/z 7763.6 and
0.960-1.017 for peak m/z 4961.5 (Figure 8) (Inter-
cooled Stata 9.2 for Windows; Stata Corp, College Sta-
tion, TX). Two peaks with m/z values of 1060.572 and
m/z 2365.139, which decrease in the plasma of hepati-
tis E patients, had AUROC values of 0.960 and 0.829
respectively with 95% confidence intervals of 0.883-
1.037 and 0.619-1.038, respectively (Figure 8). The
ROC curves were also generated for all possible com-
binations of two markers each (n = 10), three markers
each (n = 10), four markers each (n = 5), and for all
the 5 markers. All the 26 possible combinations had
very high AUROC values, with the minimum being
0.963 (95% CI = 0.890-1.000); 17 of these combina-
tions, including the one with all 5 markers (Figure 8)
had area under curve of 1.0. Thus, these five peaks
discriminate HEV patients from healthy individuals
with high sensitivity and specificity.
It may be noted that the number of data points are
not the same on each ROC curve (Figure 8). This is not
equal to the number of specimens studied, but is equal
to the number of pairs of (1-specificity) and sensitivity
possible with different cut-offs. The highest number
possible for such data points is the number of speci-
mens studied. However, if some specimens have identi-
cal results, then the number of data points for ROC
curve is fewer. Since one of the peaks (m/z 9288.6)
shows perfect separation between patients and controls,
there may not be much point in adding other peaks to
it. This might result in an over-fitted model. However,
an alternative view may be that the observed ROC
curves are based on the particular sample studied. If one
Figure 2 Representative mass spectra showing peaks in the Reflectron Positive (RP) mode. The upper and lower panels show peak
patterns for representative plasma samples from HEV patients and healthy controls, respectively. Peaks that are upregulated or down regulated
in patients and controls in the m/z range of 600 to 2600 are shown. The peaks are marked at their respective m/z values; numbers in bold
indicate the discriminating peaks. Averaged mass spectra were generated by ClinPro Tools software (V2.0) using spectra showing the highest
number of peaks and signal-to-noise ratios. All spectra were baseline-subtracted, smoothed, normalised and realigned.
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were to study other groups of patients and controls, the
ROC curves for those could deviate from the observed
curves (e.g. area-under-curve for each ROC curve have a
standard deviation around the observed value). The
combined ROC curve, being based on five peaks, is
likely to have a lower variance.
Identification of peptides using MS-MS
Potential biomarker peptides discovered by the Clinpro
Tools software were subjected to in-depth fragment ana-
lysis using the TOF/TOF capabilities of the Ultraflex.
BioTools software was also used for peptide identifica-
tion by database search. Some of the peptides that were
downregulated in acute HEV infection were identified
as: m/z 904.457, Bradykinin; m/z 1060.572, Bradykinin;
m/z 1076.567, Bradykinin; m/z 1098.6, Complement C3;
m/z 1211.660, Complement C3f; m/z 1498.794, Comple-
ment C4; m/z 2365.139, Kininogen. Peptides with m/z
759.362, 887.466, 935.396, 4961.5, 7763.6 and 9288.6,
which were predominantly present in the plasma of
HEV infected patients, could not be identified by MS/
MS. This could be because the peptide mass observed
might belong to a degraded or modified part of a novel
or uncharacterised protein. Searching the MALDI-TOF/
TOF spectrum against the mammalian and the viral
database and with no restriction in taxonomy through
NCBI also did not result in a reliable identification of
these peptides.
Discussion
While HEV mainly causes self-limiting sporadic and epi-
demic acute viral hepatitis, a more severe fulminant
hepatic failure (FHF) is seen in some patients [12].
Further, chronic liver disease patients superinfected with
HEV also show higher morbidity and mortality [13].
During pregnancy, hepatitis E is associated with
increased frequency of severe liver disease, mortality and
adverse fetal outcomes than disease caused by other
hepatitis viruses [14]. An increase in estrogen, progester-
one and b-HCG levels was observed in HEV-positive
pregnant patients with FHF compared to HEV-negative
patients and controls [15]. This alteration in hormones
may enhance viral replication, leading to severe liver dis-
ease during pregnancy [16]. Severe liver damage follow-
ing HEV infection has also been correlated to the
absence of NF-B p65 subunit [17]. These observations
suggest that the severity of HEV infection is influenced
by the host response; identifying disease related host sig-
natures would thus be important to understand disease
pathogenesis and improving prognosis.
Figure 3 Representative mass spectra showing peaks in the Reflectron Positive (RP) mode. The upper and lower panels show peak
patterns for representative plasma samples from HEV patients and healthy controls, respectively. Peaks in the m/z range of 700 to 1100 are
shown. The upper and lower panels show peak patterns for representative plasma samples from HEV patients and healthy controls, respectively.
Averaged mass spectra were generated by ClinPro Tools software (V2.0) using spectra showing the highest number of peaks and signal-to-noise
ratios. All spectra were baseline-subtracted, smoothed, normalised and realigned. Insets show discriminating peaks not readily apparent at the
scale of the main figure.
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The plasma peptidome contains protein fragments
derived from cells and tissues. While some researchers
have dismissed the peptidome as ‘biological trash’,
recent work has indicated that it may shed light on
pathophysiological perturbations to host physiology and
biochemical regulatory networks, and may lead to the
identification of diagnostic biomarkers [8-10,18].
Since blood plasma is a complex body fluid [19], we
used a magnetic bead based fractionation strategy to
simplify the plasma peptidome. Beads coated with C18
were used to enrich hydrophobic peptides from each
sample, for which a peptide mass fingerprint (PMF) was
generated. The analysis led to an averaged peptide pat-
tern for controls and tests (HEV samples) and a specific
pattern representative of hepatitis E was discovered.
Analysis using different acquisition modes identified 14
unique peaks that were differentially regulated during
acute hepatitis E. This peptide pattern was further vali-
dated using blinded assessment of other plasma samples
and classifying peptides with m/z values of 9288.6,
7763.6, 4961.5, 1060.572 and 2365.139 were identified.
Of these, the first three unidentified peptides were
increased, while the other two, identified as kininogen
and bradykinin, were decreased in the plasma of hepati-
tis E patients.
The innate immune system is the first line of defence,
comprising of cells and mechanisms that defend the
host from infection in a non-specific manner. Inflamma-
tion is one of the first responses to infection or irrita-
tion. Various chemical factors released by injured cells
stimulate an inflammatory response and serve to estab-
lish a physical barrier against the spread of infection,
and promote healing of any damaged tissue following
the clearance of pathogens [20]. A number of chemical
factors such as histamine, bradykinin, serotonin and
prostaglandins are produced during inflammation, which
sensitize pain receptors, cause vasodilation at the scene,
and attract phagocytes. The kinin forming pathway is
activated on endothelial cells and neutrophils when high
molecular weight kininogen (HK) is cleaved by plasma
kallikrein liberating bradykinin, a potent mediator of
inflammation [21]. Another arm of the innate immune
Figure 4 Representative mass spectra showing peaks in the Reflectron Positive (RP) mode. The upper and lower panels show peak
patterns for representative plasma samples from HEV patients and healthy controls, respectively. Peaks in the m/z range of 1050 to 1800 are
shown. The upper and lower panels show peak patterns for representative plasma samples from HEV patients and healthy controls, respectively.
Averaged mass spectra were generated by ClinPro Tools software (V2.0) using spectra showing the highest number of peaks and signal-to-noise
ratios. All spectra were baseline-subtracted, smoothed, normalised and realigned. Insets show discriminating peaks not readily apparent at the
scale of the main figure.
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system comprises of complement proteins that also link
to the adaptive immune response. This cascade is com-
posed of many plasma proteins synthesized by hepato-
cytes. Thus any perturbation such as a viral infection in
the liver should trigger a strong innate response as the
first line of host defence. In this study, the levels of
complement proteins C3, C3f, C4, and bradykinin and
kininogen were found to be lower in the plasma of
hepatitis E patients compared to healthy controls. The
exact mechanism for this reduction is not understood at
this time.
We previously reported profiling the plasma and
urine proteomes of hepatitis E patients and identified
various proteins that could reliably identify the acute
phase of disease [22]. On combining results from that
study and the present one, several differentially regu-
lated proteins were identified during acute HEV infec-
tion. These belong to different classes namely, acute
phase proteins (APP), lipocalins, proteins involved in
lipoprotein metabolism and complement proteins
(Figure 9). HEV infection modulates the acute phase
response, a major inflammatory pathway in the liver as
observed from the decrease in positive APPs like hap-
toglobin, hemopexin, serum amyloid P precursor and
alpha-1 acid glycoprotein, and increase in the anti-
inflammatory negative APP, alpha-2-HS glycoprotein
(or fetuin). A direct effect of the HEV open reading
frame 3 (ORF3) protein has been proposed on the
expression of APPs [23].
Infection by HEV also results in modulation of the
lipocalin family of proteins. These are a group of small
extracellular ligand binding proteins with diverse func-
tional and structural properties. These involve retinol
transport (retinol binding protein), prostaglandin synth-
esis (prostaglandin D2 synthase), regulation of cell
homeostasis and immune response (alpha-1-microglobu-
lin, alpha-1-acid glycoprotein, transthyretin) [24-26]. In
our proteome analysis of urine and plasma from hepati-
tis E patients, these proteins were differentially modu-
lated [22], as indicated in Figure 9.
Figure 5 Representative mass spectra showing peaks in the Linear Positive (LP) mode. The upper and lower panels show peak patterns
for representative plasma samples from HEV patients and healthy controls, respectively. Peaks that are upregulated or down regulated in
patients and controls in the m/z range of 1000 to 10000 are shown. The peaks are marked at their respective m/z values; numbers in bold
indicate the discriminating peaks. Averaged mass spectra were generated by ClinPro Tools software (V2.0) using spectra showing the highest
number of peaks and signal-to-noise ratios. All spectra were baseline-subtracted, smoothed, normalised and realigned. Insets show discriminating
peaks not readily apparent at the scale of the main figure.
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Figure 6 Representative mass spectra showing peaks in the Linear Positive (LP) mode. The upper and lower panels show peak patterns
for representative plasma samples from HEV patients and healthy controls, respectively. Peaks that are upregulated or down regulated in
patients and controls in the m/z range of 4000 to 10000 are shown. The peaks are marked at their respective m/z values; numbers in bold
indicate the discriminating peaks. Averaged mass spectra were generated by ClinPro Tools software (V2.0) using spectra showing the highest
number of peaks and signal-to-noise ratios. All spectra were baseline-subtracted, smoothed, normalised and realigned.
Figure 7 Density Plot of the peptide profiles. Density plots (pseudo gel view) of the plasma peptide profiles of HEV patients and healthy
controls are shown. Differentiating peaks that are identified using the (A) RP mode, and (B) LP mode are marked with arrows. Upper panels are
the gel views of control samples and lower panels represent the patient samples. The MS profiles were generated by ClinPro Tools software
(V2.0) and were baseline-subtracted, smoothed, and normalised.
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Figure 8 Receiver Operator Characteristics Curve (ROC) for the discriminating peaks. The Area under the curve (AUROC) for peaks with m/
z values indicated on the graphs is shown. These are 1.00 for m/z 9288.6 and 0.954 for m/z 7763.6 and 0.989 for m/z 4961.5. Peak m/z 1060.572
was identified as Bradykinin with an AUROC value of 0.960; peak m/z 2365.139 was identified as Kininogen with an AUROC value of 0.829. The
AUROC value for all 5 peaks taken together is 1.0.
Figure 9 Differentially regulated proteins in HEV infected patients. An overview of the various pathways perturbed due to hepatitis E virus
infection is presented. The plain and italicized texts indicate increased or decreased expression of the proteins, respectively, in patients
compared to controls.
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Apolipoproteins are lipid binding proteins that trans-
port dietary lipids through the bloodstream from the
intestine to liver or endogenously synthesized lipids
from the liver to other tissues for storage (adipocytes),
metabolism (muscle, heart, lung) or secretion, and play
an important role in lipid metabolism. During the acute
phase response, there is a decrease in apoA-I, apoA-II
and apoC levels [27-29], whereas apoE is increased in
some studies [27,30], but decreased in others [31]. We
also observed a decrease in apoA-I levels and an
increase in apoE levels in the plasma of acute hepatitis
E patients compared to healthy controls [22].
The mechanistic details of these changes or a direct
involvement of HEV proteins are presently not under-
stood. This study in combination with the earlier ana-
lyses of the plasma and urine proteomes further
strengthens the observation that HEV suppresses innate
responses to establish infection and replicate in the
host. This effect is likely to be short-lived since HEV
causes only an acute self-limiting infection, except in
immunologically compromised hosts where it can also
cause a chronic infection [32-34]. This constitutes the
first such study on HEV and hepatitis E, which allows
insights into viral pathogenesis and also provides bio-
markers which can be used to reliably identify hepatitis
E patients.
There are some limitations of the present study. We
have used only male patients in this study due to the
major location of our sampling, and have compared
only hepatitis E patients to healthy controls. We cannot
therefore say whether the peptide signatures discovered
here are specific for hepatitis E or they would also be
found in other forms of hepatitis. Further, our separa-
tion method utilizes beads that capture only hydropho-
bic peptides. There could be other potential marker
peptides with different chemical properties. Finally, we
have validated the discovered signatures using the same
separation and mass spectrometric approach instead of
another platform. Notwithstanding these limitations, this
study provides an important methodological platform
for further discovery, which will be used in future to
compare fulminant and self-limited hepatitis E patients.
Conclusions
This study compared the plasma peptidome of hepatitis
E patients to healthy controls. Using mass spectrometric
analysis of the peptides we have identified a signature
comprising of five potential biomarker peaks that could
reliably identify patients and controls. We have also
identified a number of peptides that are differentially
regulated in hepatitis E disease and which are degraded
or processed products of some of the key players of
host innate immunity. Besides identifying potential bio-
marker peptides, this study and an earlier one reported
from our group [22] have helped increase our under-
standing of hepatitis E disease pathogenesis and the pos-
sible host pathways perturbed by the hepatitis E virus
for its own survival.
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